Oxford researchers question whether molnupiravir is saving lives
A large open-label trial shows the antiviral is not any better than usual care
Molnupiravir does not appear to reduce deaths or hospitalisation in high-risk vaccinated adults with COVID-19 compared with usual care, according to the largest randomised trial of the agent to date.
The oral antiviral (Lagevrio) has been a key part of Australia’s recent defence in the pandemic, with more than 237,000 scripts dispensed.
